Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03017131CT.gov Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
NCT02650986CT.gov Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | — | Active Not Recruiting | — | — | — |
NCT01673217CT.gov Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Decitabine (this asset) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P2 | BB · 64 |
| Trabectedin | AGO Research GmbH | P4 | BBB |
| Mirvetuximab Soravtansine | AstraZeneca | P3 | BBB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BB |
| Olaparib | Imunon | P4 | BB |
| Carboplatin | University of Washington | P3 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Durvalumab | AGO Research GmbH | P2 | BB |
| Lenvatinib | University Medical Center Groningen | P4 | BB |
+42 more in the Ovarian Carcinoma cohort
Other indications for Decitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BBB · 72 |
| Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation | — | P3 | BB · 70 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Decitabine in Ovarian Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/decitabine-ovarian-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →